On this page
Deep Dive — Evidence Details
Bottom Line
- ▸[[Metformin]] is the preferred initial therapy for most patients due to its efficacy, safety, and cost-effectiveness [67, 86].
- ▸Early use of [[SGLT2 inhibitors]] or [[GLP-1 receptor agonists]] is recommended for patients with established ASCVD, heart failure, or CKD to reduce major adverse cardiovascular events and renal progression [2, 3, 80].
- ▸[[Tirzepatide]] and high-dose [[semaglutide]] offer superior weight loss and glycemic reduction compared to standard monotherapies [4, 48, 51].
remains the standard first-line pharmacological treatment for adults with new-onset type 2 diabetes mellitus due to its established safety, low cost, and efficacy in reducing hepatic gluconeogenesis [67]A1a[83]D5[86]D5. For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), guidelines now emphasize a complications-centric approach, recommending the early initiation of or regardless of baseline HbA1c [80]A1c.
Comparative Efficacy and Outcomes
In treatment-naive patients, monotherapy effectively lowers HbA1c, though its effect size varies by genetic factors such as the SLC47A1 rs2289669 variant (MD -0.55%; 95% CI, -0.91 to -0.20) [5]A1a. Compared to other agents, like 1.0 mg provide superior glycemic control and weight loss over like 25 mg (ETD -0.61% HbA1c and -1.65 kg weight) [4]A1a. Dual agonists such as demonstrate even greater potency, with HbA1c reductions up to 2.07% and weight loss of 14.7% at maximum doses [50]A1b[51]A1b.
| Outcome | Intervention | Effect Size (HR/RR) | NNT/NNH |
|---|---|---|---|
| MACE | HR 0.87 (0.81-0.93) [2]A1a | NNT not calculable | |
| All-Cause Mortality | HR 0.88 (0.83-0.93) [2]A1a | NNT not calculable | |
| Kidney Failure | HR 0.84 (0.72-0.99) [2]A1a | NNT not calculable | |
| MACE | HR 0.90 (0.85-0.96) [23]A1a | NNT not calculable | |
| HF Hospitalization | HR 0.77 (0.68-0.85) [23]A1a | NNT not calculable |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line Agent | as universal first-line (ADA/EASD) [84]D5 | Complications-centric (SGLT2i/GLP-1RA) first-line (AACE) [80]A1c | High | Choice depends on cardiovascular/renal risk profile |
Pearl: While is the traditional first-line agent, and are now preferred first-line or early add-on therapies for patients with high cardiovascular or renal risk due to their proven mortality and organ-protective benefits [2]A1a[3]A1a[80]A1c. (High, multiple meta-analyses and RCTs)
| Outcome | Intervention | Effect Size (HR/RR) | NNT/NNH |
|---|---|---|---|
| MACE | HR 0.87 (0.81-0.93) [2]A1a | (NNT not calculable) | |
| All-Cause Mortality | HR 0.88 (0.83-0.93) [2]A1a | (NNT not calculable) | |
| Kidney Failure | HR 0.84 (0.72-0.99) [2]A1a | (NNT not calculable) | |
| MACE | HR 0.90 (0.85-0.96) [23]A1a | (NNT not calculable) | |
| HF Hospitalization | HR 0.77 (0.68-0.85) [23]A1a | (NNT not calculable) |
Background: Evolution of Treatment
- ▸Metformin remains the historical first-line standard due to its safety profile and the 1998 UKPDS cardiovascular data.
- ▸The 2008 ACCORD trial shifted the paradigm away from intensive HbA1c targets (<6.0%) after demonstrating increased mortality.
- ▸SGLT2 inhibitors and GLP-1 RAs have emerged as preferred agents for patients with established cardiovascular or renal risk regardless of baseline HbA1c.
The of new-onset type 2 diabetes has transitioned from a glucose-centric model to a complications-centric approach, driven by landmark evidence regarding cardiovascular and renal protection. Historically, has served as the foundational first-line therapy due to its robust glucose-lowering effects, established safety, and low cost [83]D5[86]D5. Its status was solidified by the 1998 UK Prospective Diabetes Study (UKPDS), which identified long-term cardiovascular benefits [83]D5.
The Shift from Intensive Glycemia to Risk Mitigation
In the early 2000s, the focus was on achieving near-normal HbA1c levels. However, the ACCORD trial (2008) demonstrated that intensive therapy targeting an HbA1c below 6.0% actually increased mortality (HR 1.22, 95% CI 1.01-1.46) compared to standard therapy [92]A1b. This finding identified a previously unrecognized harm of aggressive glucose lowering in high-risk patients, leading to more individualized targets [92]A1b.
Emergence of Incretins and SGLT2 Inhibitors
The therapeutic landscape shifted with the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists ( ). Landmark trials such as LEADER (2016) for and SUSTAIN-6 for established that these agents reduce major adverse cardiovascular events (MACE) by approximately 12% to 13% [2]A1a[29]A1a[38]A1b. Similarly, SGLT2 inhibitors demonstrated a 23% reduction in the composite of heart failure hospitalization or cardiovascular death (HR 0.77, 95% CI 0.68-0.85), with a NNT of 39 to prevent one such event over 2.6 years in high-risk populations [23]A1a[37]A1b.
Abandoned Approaches
Several older classes have been largely abandoned as first-line options:
- Sulfonylureas: While effective for glucose lowering, they are associated with a higher risk of severe hypoglycemia (2.2% vs 0.7% for ) and may cause earlier insulin dependence in certain phenotypes [41]A1b[94]A1a.
- Sliding-Scale Insulin (SSI): In the inpatient setting, the RABBIT 2 trial (2007) proved that a basal-bolus regimen is superior to SSI, which failed to achieve glucose targets in 62% of patients [88]A1b.
- Biguanide Precursors: Phenformin and buformin were discontinued in the 1970s due to high risk, leaving as the sole widely used biguanide [83]D5.
Pearl: Modern therapy prioritizes agents with proven organ protection, such as SGLT2 inhibitors and GLP-1 RAs, over older agents like sulfonylureas that carry higher hypoglycemia risks [2]A1a[23]A1a[41]A1b.
| Year | Trial/Study | Finding | Clinical Impact |
|---|---|---|---|
| 1998 | UKPDS | Metformin CV benefit | Established metformin as first-line |
| 2008 | ACCORD | Intensive HbA1c <6.0% increased mortality | Shifted focus to individualized targets |
| 2016 | LEADER | Liraglutide reduced MACE (HR 0.87) | Validated GLP-1 RA for CV protection |
| 2020 | FIDELIO-DKD | Finerenone reduced CKD progression (HR 0.82) | Introduced nonsteroidal MRAs for renal care |
Current Evidence and Standard
- ▸Metformin is the standard first-line agent due to its safety, efficacy, and low cost, though genetic variants can significantly alter individual glycemic response.
- ▸Initial dual therapy with metformin and an SGLT2 inhibitor increases the odds of reaching HbA1c targets (OR 1.41) compared to metformin monotherapy.
- ▸GLP-1 receptor agonists and SGLT2 inhibitors provide significant cardiovascular and renal protection (12-13% reduction in MACE) independent of their glucose-lowering effects.
remains the standard first-line pharmacological treatment for adults with new-onset type 2 diabetes, supported by its established safety profile, low cost, and weight neutrality [83]D5[84]D5. While its primary mechanism involves inhibiting hepatic gluconeogenesis [86]D5, clinical response is variable and may be influenced by genetic factors such as the SLC47A1 rs2289669 variant, where A carriers show a significantly greater HbA1c reduction (MD -0.55%; 95% CI -0.91 to -0.20) compared to GG homozygotes [5]A1a.
Initial Monotherapy vs. Combination Therapy
Recent evidence suggests that initial dual therapy may be superior to metformin monotherapy for achieving glycemic targets [74]A1a. In treatment-naive patients, the proportion achieving an HbA1c of 7.0% or less was 86% with initial dual therapy compared to 81% with metformin alone (OR 1.41, p = 0.001) [74]A1a. Specifically, combining metformin with a sodium-glucose cotransporter 2 (SGLT2) inhibitor like (12.5 mg twice daily) resulted in HbA1c reductions of 1.9% to 2.1%, significantly greater than the 1.2% to 1.8% seen with metformin monotherapy [17]A1b.
Comparative Efficacy of Add-on Agents
When metformin monotherapy is insufficient, the choice of a second agent is increasingly guided by comorbidities such as cardiovascular disease (CVD), chronic kidney disease (CKD), or obesity [80]A1c. The GRADE trial demonstrated that and were modestly more effective than or at maintaining HbA1c below 7.0% over 5 years [41]A1b.
| Drug Class | Representative Agent | HbA1c Reduction | Weight Change | Key Outcome |
|---|---|---|---|---|
| GLP-1 RA | -1.5% [14]A1b | -5.6 kg [14]A1b | 12% reduction in MACE (HR 0.88) [29]A1a | |
| SGLT2i | -0.9% [15]A1b | -3.8 kg [15]A1b | 50% reduction in HHF (HR 0.50) [85]B2b | |
| Dual GIP/GLP-1 | -1.87% to -2.07% [51]A1b | -7.0 to -9.5 kg [51]A1b | Noninferior to dulaglutide for MACE [103]A1b | |
| DPP-4i | -0.5% to -0.9% [41]A1b[64]A1b | Neutral [41]A1b | Lower risk of hypoglycemia than sulfonylureas [41]A1b |
Cardiovascular and Renal Protection
GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors provide independent and additive benefits for cardiorenal protection [3]A1a. GLP-1 RAs reduce major adverse cardiovascular events (MACE) by 13% (HR 0.87, 95% CI 0.81-0.93) and all-cause mortality by 12% (HR 0.88, 95% CI 0.83-0.93) [2]A1a. SGLT2 inhibitors like (10 mg daily) reduce the risk of kidney failure or cardiovascular death in patients with CKD, with a consistent effect in those with (HR 0.64) and without (HR 0.50) type 2 diabetes [36]A1b. For patients with concomitant and diabetes, SGLT2 inhibitors are associated with a reduction in all-cause mortality (HR 0.532) [100]B2b.
Weight and Metabolic Health
For patients where weight loss is a primary goal, and high-dose (2.4 mg) show superior efficacy [4]A1a[49]A1b. (15 mg) achieved HbA1c reductions of up to 2.11% and weight loss of 10.1 kg in monotherapy trials [51]A1b. In patients with non-alcoholic steatohepatitis (NASH), (10 mg) significantly reduced liver fat by 4.0% compared to standard care [20]A1b, while (1.8 mg) led to NASH resolution in 39% of patients versus 9% with placebo [55]A1b.
Controversies and Guideline Disagreement
While metformin is the traditional first-line agent, some experts and guidelines (e.g., AACE 2023) now advocate for a complications-centric approach that may prioritize SGLT2 inhibitors or GLP-1 RAs as first-line therapy in patients with established ASCVD, heart failure, or CKD [80]A1c[100]B2b.
| Question | Position A (Traditional) | Position B (Complications-Centric) | Strength | Implication |
|---|---|---|---|---|
| First-line agent | Metformin for all [83]D5[84]D5 | SGLT2i/GLP-1RA if high risk [80]A1c[100]B2b | Moderate | Shift toward individualized therapy |
| Initial therapy | Monotherapy first [67]A1a | Early dual therapy [74]A1a | Moderate | Faster attainment of HbA1c targets |
Pearl: Metformin remains the foundational first-line therapy, but initial dual therapy with an SGLT2 inhibitor or GLP-1 receptor agonist provides superior glycemic control and should be prioritized in patients with high cardiovascular or renal risk [2]A1a[3]A1a[74]A1a.
| Drug Class | Representative Agent | HbA1c Reduction | Weight Change | Key Outcome |
|---|---|---|---|---|
| GLP-1 RA | -1.5% | -5.6 kg | 12% reduction in MACE (HR 0.88) | |
| SGLT2i | -0.9% | -3.8 kg | 50% reduction in HHF (HR 0.50) | |
| Dual GIP/GLP-1 | -1.87% to -2.07% | -7.0 to -9.5 kg | Noninferior to dulaglutide for MACE | |
| DPP-4i | -0.5% to -0.9% | Neutral | Lower hypoglycemia risk than sulfonylureas |
Applicability and Caveats
- ▸Metformin dosing must be reduced to 500-1500 mg daily in CKD stages 3-4 to maintain safe plasma concentrations below 5.0 mg/L.
- ▸Liraglutide reduces MACE specifically in patients with established cardiovascular disease (HR 0.81), with less evidence for primary prevention.
- ▸SGLT2 inhibitors combined with insulin may reduce the risk of diabetic macular oedema, whereas GLP-1 receptor agonists may increase retinopathy risk in insulin-treated populations.
The selection of first-line therapy must account for specific comorbidities, as the cardiorenal benefits of newer agents often outweigh the glycemic utility of in high-risk populations. While remains the foundational therapy for most, the American College of Physicians (ACP) now recommends adding an or in adults with inadequate glycemic control to reduce all-cause mortality and major adverse cardiovascular events (MACE) [114]A1c.
Renal Impairment and Chronic Kidney Disease
use in (CKD) requires strict dose adjustment based on estimated glomerular filtration rate (eGFR) to mitigate the risk of . Safe daily dosing schedules are 1500 mg for CKD stage 3A, 1000 mg for stage 3B, and 500 mg for stage 4 [122]B2b. Despite historical reluctance, observational data suggest may be renoprotective, reducing the risk of doubling serum creatinine (HR 0.71) and progression to end-stage kidney disease (ESKD) (HR 0.55, 95% CI 0.47-0.66) [118]B3b. In the SURPASS-4 trial, (5-15 mg weekly) significantly slowed eGFR decline compared to (-1.4 vs -3.6 mL/min/1.73 m2 per year; difference 2.2, 95%) [98]A1b.
Cardiovascular and Metabolic Subgroups
For patients with established atherosclerotic cardiovascular disease (ASCVD), reduces MACE risk (HR 0.81, 95% CI 0.71-0.92), though this benefit is less pronounced in those without prior MACE (HR 0.96) [117]B2b. In patients with metabolic dysfunction-associated steatotic liver disease ( ), is a discriminative factor for identifying the condition [119]B3b, while (300 μg) has shown improvements in liver fibrosis scores and AST/ALT levels compared to placebo [111]A1b.
Pregnancy and Cognitive Health
In preconception care for women with type 2 diabetes, and are the only recommended pharmacological treatments; all other agents should be discontinued before conception [138]A1c. Regarding cognitive outcomes, intensive glycemic control does not appear to reduce the incidence of (RR 1.27, 95% CI 0.87-1.85) or significant cognitive decline over five years compared to standard care [127]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line in high CV risk | Metformin as foundation for all [84]D5[128]A1c. | SGLT2i or GLP-1RA as monotherapy regardless of HbA1c [125]D5. | Moderate | Shift toward earlier use of cardioprotective agents. |
| GLP-1RA and Retinopathy | No significant risk identified in major trials [110]B2b. | Increased risk of (HR 1.308) when used with insulin [136]B3b. | Low | Requires monitoring in patients on insulin. |
Pearl: Clinical selection should prioritize SGLT2 inhibitors or GLP-1 receptor agonists in patients with CKD or high cardiovascular risk, as these agents provide mortality benefits independent of metformin [114]A1c[121]A1a. Metformin remains safe in moderate CKD (Stage 3) provided the dose is adjusted to 1000-1500 mg daily [122]B2b.
| CKD Stage | eGFR Range | Recommended Metformin Dose |
|---|---|---|
| Stage 3A | 45-59 mL/min | 1500 mg daily (500 mg AM, 1000 mg PM) |
| Stage 3B | 30-44 mL/min | 1000 mg daily (500 mg AM, 500 mg PM) |
| Stage 4 | 15-29 mL/min | 500 mg daily (AM) |
On the Horizon
- ▸Triple-receptor agonists like retatrutide and oral non-peptide GLP-1RAs like orforglipron are demonstrating potent phase 2 efficacy in weight and glucose reduction.
- ▸The UKPDS 91 follow-up confirms that the metabolic legacy of early intensive control with metformin or sulfonylureas lasts at least 24 years.
- ▸Emerging data suggest SGLT2 inhibitors and GLP-1 receptor agonists may provide superior cognitive protection and dementia risk reduction compared to other agents.
Emerging evidence is shifting the therapeutic focus from simple glycemic control to multi-receptor agonism and metabolic preservation. , a dual GIP/GLP-1 receptor agonist, has demonstrated superior glycemic control compared to 1 mg, primarily through enhanced suppression of fasting glucose and improved insulin secretion rates [140]A1b. In post hoc analyses of the SURPASS program, achieved similar improvements in HbA1c (-2.6% vs -2.4%) and body weight (-14 kg vs -13 kg) in patients with early-onset versus later-onset disease [144]B2b. Factors associated with achieving a weight reduction of ≥15% include higher doses, female sex, and background therapy [151]B2b.
Novel Multi-Receptor Agonists and Combinations
Next-generation agents targeting three or more pathways are in clinical development:
- : This GIP, GLP-1, and glucagon receptor agonist showed clinically meaningful glucose and weight-lowering efficacy in phase 2 trials [53]A1b.
- : A dual glucagon/GLP-1 receptor agonist that reduced HbA1c by up to 1.71% and body weight by 8.7% over 16 weeks [59]A1b.
- : An oral, non-peptide GLP-1 receptor agonist that achieved HbA1c reductions of up to 2.10% at 26 weeks [57]A1b.
- CagriSema: The combination of and the amylin analogue (2.4 mg each) reduced body weight by 15.6%, significantly exceeding the effect of either component alone [56]A1b.
Long-term Legacy and Cognitive Outcomes
Extended follow-up of the UKPDS (UKPDS 91) confirms that the "legacy effect" of early intensive glycemic control persists for up to 24 years after trial conclusion, with sustained relative risk reductions for death from any cause (10%) and myocardial infarction (17%) [155]A1b. Beyond cardiovascular health, network meta-analyses suggest that and are associated with a reduced risk of dementia compared to non-users, potentially offering superior cognitive prognosis over older agents [162]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line in Youth | Metformin remains standard first-line [163]D5. | Metformin is suboptimal in >50% of youth; early use of GLP-1RA/SGLT2i is urged [164]D5. | Expert Perspective | Potential shift toward earlier combination therapy in pediatric populations. |
| Observational data suggested metformin reduces cancer risk [166]D5. | Large phase 3 trials and bias-adjusted studies show no survival benefit in breast or other cancers [166]D5. | High (RCT) | Metformin should not be repurposed for cancer prevention or adjuvant therapy. |
Pearl: The therapeutic horizon is moving toward triple-agonist peptides and fixed-dose combinations like CagriSema that target weight and glycemia simultaneously, while long-term data confirm that intensive early intervention yields a legacy of reduced mortality for over two decades [56]A1b[155]A1b.
| Agent | Mechanism | HbA1c Change | Weight Change |
|---|---|---|---|
| GIP/GLP-1 RA | -2.4% to -2.6% [144]B2b | -13 to -14 kg [144]B2b | |
| Glucagon/GLP-1 RA | -1.71% [59]A1b | -8.7% [59]A1b | |
| Oral GLP-1 RA | Up to -2.10% [57]A1b | Up to -10.1 kg [57]A1b | |
| CagriSema | Amylin/GLP-1 RA | -2.2% [56]A1b | -15.6% [56]A1b |
References
- [1]
Uhl S, Choure A, Rouse B et al.. “Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37987208 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [2]
Badve SV, Bilal A, Lee MMY et al.. “Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.” The lancet. Diabetes & endocrinology (2024). PMID: 39608381 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [3]
Apperloo EM, Neuen BL, Fletcher RA et al.. “Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.” The lancet. Diabetes & endocrinology (2024). PMID: 38991584 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [4]
Lingvay I, Capehorn MS, Catarig AM et al.. “Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827435 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [5]
Kim H, Bae S, Yoon HY et al.. “Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35639991 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [6]
Zhou Y, Huang Y, Ji X et al.. “Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31822895 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [7]
Khunti K, Seidu S, Kunutsor S et al.. “Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis.” Diabetes care (2017). PMID: 28801474 ↗
L2SR_OBSCited in: Bottom Line, Current Evidence and Standard - [8]
Rodbard HW, Lingvay I, Reed J et al.. “Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29688502 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [9]
Frias JP, De Block C, Brown K et al.. “Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).” The Journal of clinical endocrinology and metabolism (2024). PMID: 38252888 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [10]
Wittert GA, Robledo KP, Handelsman DJ et al.. “Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39928571 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [11]
Lingvay I, Bache JK, Desouza CV et al.. “Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40102962 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [12]
Whyte MB, Shojaee-Moradie F, Sharaf SE et al.. “Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30215735 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [13]
Shehadeh N, Galassetti P, Iqbal N et al.. “Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up).” The Journal of clinical endocrinology and metabolism (2025). PMID: 39446459 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [14]
Ahmann AJ, Capehorn M, Charpentier G et al.. “Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.” Diabetes care (2017). PMID: 29246950 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [15]
Rodbard HW, Rosenstock J, Canani LH et al.. “Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.” Diabetes care (2019). PMID: 31530666 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [16]
Nauck MA, Petrie JR, Sesti G et al.. “A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.” Diabetes care (2015). PMID: 26358288 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [17]
Hadjadj S, Rosenstock J, Meinicke T et al.. “Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 27493136 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [18]
Zhang B, Cheng Z, Chen J et al.. “Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Diabetes care (2024). PMID: 37943529 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [19]
Halden TAS, Kvitne KE, Midtvedt K et al.. “Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.” Diabetes care (2019). PMID: 30862658 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [20]
Kuchay MS, Krishan S, Mishra SK et al.. “Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).” Diabetes care (2018). PMID: 29895557 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [21]
Garvey WT, Birkenfeld AL, Dicker D et al.. “Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.” Diabetes care (2020). PMID: 32139381 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [22]
Zinman B, Aroda VR, Buse JB et al.. “Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.” Diabetes care (2019). PMID: 31530667 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [23]
Ferreira JP, Oliveira AC, Saraiva FA et al.. “Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis.” European journal of endocrinology (2021). PMID: 33769961 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [24]
Stomby A, Otten J, Ryberg M et al.. “Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32069218 ↗
L2RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [25]
Ajjan RA, Hensor EMA, Del Galdo F et al.. “Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.” European journal of endocrinology (2022). PMID: 35113805 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [26]
van Raalte DH, Bunck MC, Smits MM et al.. “Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.” European journal of endocrinology (2016). PMID: 27466218 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [27]
Smits MM, Tonneijck L, Muskiet MH et al.. “Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.” European journal of endocrinology (2016). PMID: 27777261 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [28]
Lemieux P, Weisnagel SJ, Caron AZ et al.. “Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial.” European journal of endocrinology (2019). PMID: 31344685 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [29]
Kristensen SL, Rørth R, Jhund PS et al.. “Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.” The lancet. Diabetes & endocrinology (2019). PMID: 31422062 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [30]
Sorli C, Harashima SI, Tsoukas GM et al.. “Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.” The lancet. Diabetes & endocrinology (2017). PMID: 28110911 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [31]
Kadowaki T, Isendahl J, Khalid U et al.. “Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.” The lancet. Diabetes & endocrinology (2022). PMID: 35131037 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [32]
Mu Y, Bao X, Eliaschewitz FG et al.. “Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.” The lancet. Diabetes & endocrinology (2024). PMID: 38330988 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [33]
Gastaldelli A, Cusi K, Fernández Landó L et al.. “Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.” The lancet. Diabetes & endocrinology (2022). PMID: 35468325 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [34]
le Roux CW, Steen O, Lucas KJ et al.. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The lancet. Diabetes & endocrinology (2024). PMID: 38330987 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [35]
Heise T, Mari A, DeVries JH et al.. “Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.” The lancet. Diabetes & endocrinology (2022). PMID: 35468322 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [36]
Wheeler DC, Stefánsson BV, Jongs N et al.. “Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.” The lancet. Diabetes & endocrinology (2021). PMID: 33338413 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [37]
Bakris GL, Agarwal R, Anker SD et al.. “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.” The New England journal of medicine (2020). PMID: 33264825 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [38]
Marso SP, Daniels GH, Brown-Frandsen K et al.. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2016). PMID: 27295427 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [39]
Bi Y, Li M, Liu Y et al.. “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.” The New England journal of medicine (2024). PMID: 39555827 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [40]
Davies MJ, Bajaj HS, Broholm C et al.. “Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40544432 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [41]
Nathan DM, Lachin JM, Balasubramanyam A et al.. “Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.” The New England journal of medicine (2022). PMID: 36129996 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [42]
Pittas AG, Dawson-Hughes B, Sheehan P et al.. “Vitamin D Supplementation and Prevention of Type 2 Diabetes.” The New England journal of medicine (2019). PMID: 31173679 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [43]
Kudva YC, Raghinaru D, Lum JW et al.. “A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40105270 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [44]
Schauer PR, Bhatt DL, Kirwan JP et al.. “Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.” The New England journal of medicine (2017). PMID: 28199805 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [45]
Arslanian SA, Hannon T, Zeitler P et al.. “Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.” The New England journal of medicine (2022). PMID: 35658022 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [46]
Steg PG, Bhatt DL, Simon T et al.. “Ticagrelor in Patients with Stable Coronary Disease and Diabetes.” The New England journal of medicine (2019). PMID: 31475798 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [47]
Green CJ, Marjot T, Walsby-Tickle J et al.. “Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.” European journal of endocrinology (2022). PMID: 35038311 ↗
L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard - [48]
Karagiannis T, Avgerinos I, Liakos A et al.. “Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.” Diabetologia (2022). PMID: 35579691 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [49]
Davies M, Færch L, Jeppesen OK et al.. “Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.” Lancet (London, England) (2021). PMID: 33667417 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [50]
Garvey WT, Frias JP, Jastreboff AM et al.. “Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.” Lancet (London, England) (2023). PMID: 37385275 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [51]
Rosenstock J, Wysham C, Frías JP et al.. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.” Lancet (London, England) (2021). PMID: 34186022 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [52]
Bonaca MP, Catarig AM, Houlind K et al.. “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2025). PMID: 40169145 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [53]
Rosenstock J, Frias J, Jastreboff AM et al.. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet (London, England) (2023). PMID: 37385280 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [54]
Kosiborod MN, Deanfield J, Pratley R et al.. “Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.” Lancet (London, England) (2024). PMID: 39222642 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [55]
Armstrong MJ, Gaunt P, Aithal GP et al.. “Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.” Lancet (London, England) (2015). PMID: 26608256 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [56]
Frias JP, Deenadayalan S, Erichsen L et al.. “Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” Lancet (London, England) (2023). PMID: 37364590 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [57]
Frias JP, Hsia S, Eyde S et al.. “Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.” Lancet (London, England) (2023). PMID: 37369232 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard, On the Horizon - [58]
Hannon TS, Chao LC, Barrientos-Pérez M et al.. “Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) (2025). PMID: 40975112 ↗
L1RCTCited in: Bottom Line, Current Evidence and Standard - [59]
Blüher M, Rosenstock J, Hoefler J et al.. “Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.” Diabetologia (2023). PMID: 38095657 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [60]
Lingvay I, Benamar M, Chen L et al.. “Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.” Diabetologia (2025). PMID: 39820580 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [61]
McCrimmon RJ, Catarig AM, Frias JP et al.. “Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.” Diabetologia (2020). PMID: 31897524 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [62]
van den Burg EL, Schoonakker MP, van Peet PG et al.. “Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.” Diabetologia (2024). PMID: 38546821 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [63]
Wang W, Bain SC, Bian F et al.. “Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.” Diabetologia (2024). PMID: 38985162 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [64]
Ji L, Agesen RM, Bain SC et al.. “Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.” Diabetologia (2024). PMID: 38985161 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [65]
Gao S, Zhang F, Xie X et al.. “Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 42211460 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [66]
Jeyaraman MM, Al-Yousif NSH, Singh Mann A et al.. “Resveratrol for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 31978258 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [67]
Gnesin F, Thuesen ACB, Kähler LKA et al.. “Metformin monotherapy for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 32501595 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [68]
Madsen KS, Kähler P, Kähler LKA et al.. “Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2019). PMID: 30998259 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [69]
Petrov MS. “DIAGNOSIS OF ENDOCRINE DISEASE: Post-pancreatitis diabetes mellitus: prime time for secondary disease.” European journal of endocrinology (2021). PMID: 33460393 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard - [70]
Lapauw B, Kaufman JM. “MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.” European journal of endocrinology (2020). PMID: 33105105 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard - [71]
Zaharenko L, Kalnina I, Geldnere K et al.. “Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.” European journal of endocrinology (2016). PMID: 27609360 ↗
L4OTHERCited in: Bottom Line, Current Evidence and Standard - [72]
Raptis D, Chiotis S, Papamichalis T et al.. “Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.” Current diabetes reports (2026). PMID: 42277362 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [73]
Costa TA, de Sousa LMT, Nogueira A et al.. “Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.” Heart failure reviews (2026). PMID: 42249978 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [74]
Kelly M, Saluja S, Ellis HL et al.. “A systematic review and meta-analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D).” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42165377 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [75]
Dao TP, Lung WC, Yang YZ et al.. “Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin.” Diabetes research and clinical practice (2026). PMID: 42086086 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [76]
Liu C, Mujahid O, Beneyto A et al.. “Sex differences in glycemic outcomes: a systematic review and meta-analysis of diabetes treatments.” BMJ open diabetes research & care (2026). PMID: 42020119 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [77]
Boccatonda A, D'Ardes D, Brighenti A et al.. “GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.” Diabetes research and clinical practice (2026). PMID: 42009258 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [78]
Marassi M, Pollis RM, Fadini GP. “Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41997798 ↗
L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [79]
Zhu X, Wang X, Zhang P et al.. “Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987895 ↗
L1SR_OBSCited in: Bottom Line, Current Evidence and Standard - [80]
Samson SL, Vellanki P, Blonde L et al.. “American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2023). PMID: 37150579 ↗
L1OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [81]
Frid AH, Kreugel G, Grassi G et al.. “New Insulin Delivery Recommendations.” Mayo Clinic proceedings (2016). PMID: 27594187 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [82]
Jun JE, Oh DH, Jeong IK et al.. “Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.” Frontiers in endocrinology (2026). PMID: 42388875 ↗
L2RCTCited in: Bottom Line, Current Evidence and Standard - [83]
Bailey CJ. “Metformin: historical overview.” Diabetologia (2017). PMID: 28776081 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [84]
Sanchez-Rangel E, Inzucchi SE. “Metformin: clinical use in type 2 diabetes.” Diabetologia (2017). PMID: 28770321 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats - [85]
Htoo PT, Tesfaye H, Schneeweiss S et al.. “Effectiveness and safety of empagliflozin: final results from the EMPRISE study.” Diabetologia (2024). PMID: 38509341 ↗
L2OTHERCited in: Bottom Line, Current Evidence and Standard - [86]
LaMoia TE, Shulman GI. “Cellular and Molecular Mechanisms of Metformin Action.” Endocrine reviews (2021). PMID: 32897388 ↗
L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [87]
Reinhart M, Puil L, Salzwedel DM et al.. “First-line diuretics versus other classes of antihypertensive drugs for hypertension.” The Cochrane database of systematic reviews (2023). PMID: 37439548 ↗
L1REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard - [88]
Umpierrez GE, Smiley D, Zisman A et al.. “Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).” Diabetes care (2007). PMID: 17513708 ↗
L1RCTCited in: Background: Evolution of Treatment - [89]
DeFronzo RA, Lewin A, Patel S et al.. “Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.” Diabetes care (2015). PMID: 25583754 ↗
L1RCTCited in: Background: Evolution of Treatment - [90]
Van Raalte DH, van Genugten RE, Eliasson B et al.. “The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.” European journal of endocrinology (2014). PMID: 24421302 ↗
L1RCTCited in: Background: Evolution of Treatment - [91]
Reynolds RM, Labad J, Sears AV et al.. “Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study.” European journal of endocrinology (2012). PMID: 22408122 ↗
L3RCTCited in: Background: Evolution of Treatment - [92]
Gerstein HC, Miller ME, Byington RP et al.. “Effects of intensive glucose lowering in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18539917 ↗
L1RCTCited in: Background: Evolution of Treatment - [93]
Casteràs A, Zafon C, Ciudin A et al.. “Are levothyroxine requirements lower in thyroidectomized diabetic patients on metformin treatment?” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23758637 ↗
L4OTHERCited in: Background: Evolution of Treatment - [94]
Brophy S, Brunt H, Davies H et al.. “Interventions for latent autoimmune diabetes (LADA) in adults.” The Cochrane database of systematic reviews (2007). PMID: 17636829 ↗
L1SR_OBSCited in: Background: Evolution of Treatment - [95]
Dietsche KB, Magge SN, Dixon SA et al.. “Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37967247 ↗
L2RCTCited in: Current Evidence and Standard, On the Horizon - [96]
Frias JP, Bonora E, Nevarez Ruiz L et al.. “Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).” Diabetes care (2021). PMID: 33397768 ↗
L1RCTCited in: Current Evidence and Standard - [97]
Hartman ML, Sanyal AJ, Loomba R et al.. “Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.” Diabetes care (2020). PMID: 32291277 ↗
L1RCTCited in: Current Evidence and Standard - [98]
Heerspink HJL, Sattar N, Pavo I et al.. “Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.” The lancet. Diabetes & endocrinology (2022). PMID: 36152639 ↗
L1RCTCited in: Current Evidence and Standard, Applicability and Caveats - [99]
Laffel LM, Danne T, Klingensmith GJ et al.. “Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.” The lancet. Diabetes & endocrinology (2023). PMID: 36738751 ↗
L1RCTCited in: Current Evidence and Standard, On the Horizon - [100]
Hsiao YY, Chen YY, Kuo MJ et al.. “SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39998428 ↗
L2COHORTCited in: Current Evidence and Standard - [101]
le Roux CW, Astrup A, Fujioka K et al.. “3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.” Lancet (London, England) (2017). PMID: 28237263 ↗
L1RCTCited in: Current Evidence and Standard - [102]
Frias JP, Nauck MA, Van J et al.. “Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.” Lancet (London, England) (2018). PMID: 30293770 ↗
L1RCTCited in: Current Evidence and Standard - [103]
Nicholls SJ, Pavo I, Bhatt DL et al.. “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 41406444 ↗
L1TRIAL_NONRANDOMCited in: Current Evidence and Standard - [104]
Rosenstock J, Bailey T, Connery L et al.. “Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.” The New England journal of medicine (2025). PMID: 40548694 ↗
L2TRIAL_NONRANDOMCited in: Current Evidence and Standard - [105]
Davies MJ, Aroda VR, Rosenstock J et al.. “Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.” Lancet (London, England) (2026). PMID: 42259337 ↗
L1RCTCited in: Current Evidence and Standard - [106]
Bajaj HS, Welch M, Shah P et al.. “Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.” Lancet (London, England) (2026). PMID: 42250575 ↗
L1RCTCited in: Current Evidence and Standard - [107]
Florez JC. “The pharmacogenetics of metformin.” Diabetologia (2017). PMID: 28770331 ↗
L5REVIEW_NARRATIVECited in: Current Evidence and Standard - [108]
Schwartz AV. “Diabetes, bone and glucose-lowering agents: clinical outcomes.” Diabetologia (2017). PMID: 28451714 ↗
L5REVIEW_NARRATIVECited in: Current Evidence and Standard - [109]
Rigato M, Avogaro A, Vigili de Kreutzenberg S et al.. “Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32271381 ↗
L1SR_OBSCited in: Applicability and Caveats - [110]
Pop-Busui R, Rosin SP, Butera NM et al.. “Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.” Diabetes care (2025). PMID: 40986645 ↗
L2RCTCited in: Applicability and Caveats - [111]
Nahra R, Wang T, Gadde KM et al.. “Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.” Diabetes care (2021). PMID: 34016612 ↗
L1RCTCited in: Applicability and Caveats - [112]
Santilli F, Simeone PG, Guagnano MT et al.. “Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.” Diabetes care (2017). PMID: 28912305 ↗
L1RCTCited in: Applicability and Caveats - [113]
. “Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.” Diabetes care (2016). PMID: 27208320 ↗
L1RCTCited in: Applicability and Caveats - [114]
Qaseem A, Obley AJ, Shamliyan T et al.. “Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.” Annals of internal medicine (2024). PMID: 38639546 ↗
L1GUIDELINECited in: Applicability and Caveats, On the Horizon - [115]
Frías JP, Guja C, Hardy E et al.. “Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.” The lancet. Diabetes & endocrinology (2016). PMID: 27651331 ↗
L1RCTCited in: Applicability and Caveats - [116]
Del Prato S, Kahn SE, Pavo I et al.. “Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.” Lancet (London, England) (2021). PMID: 34672967 ↗
L2TRIAL_NONRANDOMCited in: Applicability and Caveats - [117]
Svanström H, Ueda P, Melbye M et al.. “Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.” The lancet. Diabetes & endocrinology (2018). PMID: 30527909 ↗
L2COHORTCited in: Applicability and Caveats - [118]
Wang HH, Lin SH, Hung SY et al.. “Renal Protective Effect of Metformin in Type 2 Diabetes Patients.” The Journal of clinical endocrinology and metabolism (2025). PMID: 38986038 ↗
L3OTHERCited in: Applicability and Caveats - [119]
Nabrdalik K, Kwiendacz H, Irlik K et al.. “Machine Learning Identifies Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38330228 ↗
L3OTHERCited in: Applicability and Caveats - [120]
Croyal M, Saulnier PJ, Aguesse A et al.. “Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32301490 ↗
L2OTHERCited in: Applicability and Caveats - [121]
Ostrominski JW, Claggett BL, Miao ZM et al.. “Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.” Diabetes care (2025). PMID: 40019856 ↗
L1OTHERCited in: Applicability and Caveats - [122]
Lalau JD, Kajbaf F, Bennis Y et al.. “Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4.” Diabetes care (2018). PMID: 29305402 ↗
L2OTHERCited in: Applicability and Caveats - [123]
Kwon S, Kim YC, Park JY et al.. “The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.” Diabetes care (2020). PMID: 32132005 ↗
L3OTHERCited in: Applicability and Caveats - [124]
Liaw J, Harhay M, Setoguchi S et al.. “Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.” Diabetes care (2022). PMID: 35984049 ↗
L2OTHERCited in: Applicability and Caveats - [125]
Caparrotta TM, Blackbourn LAK, McGurnaghan SJ et al.. “Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.” Diabetes care (2020). PMID: 32581068 ↗
L5OTHERCited in: Applicability and Caveats - [126]
El-Damanawi R, Stanley IK, Staatz C et al.. “Metformin for preventing the progression of chronic kidney disease.” The Cochrane database of systematic reviews (2024). PMID: 38837240 ↗
L1SR_OBSCited in: Applicability and Caveats, On the Horizon - [127]
Areosa Sastre A, Vernooij RW, González-Colaço Harmand M et al.. “Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.” The Cochrane database of systematic reviews (2017). PMID: 28617932 ↗
L1SR_OBSCited in: Applicability and Caveats - [128]
de Boer IH, Khunti K, Sadusky T et al.. “Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).” Diabetes care (2022). PMID: 36189689 ↗
L1REVIEW_NARRATIVECited in: Applicability and Caveats - [129]
Standl E, Schnell O, McGuire DK et al.. “Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.” The lancet. Diabetes & endocrinology (2017). PMID: 28131656 ↗
L5REVIEW_NARRATIVECited in: Applicability and Caveats - [130]
Xie C, White JB, Huang W et al.. “Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.” Diabetes (2026). PMID: 41591292 ↗
L1RCTCited in: Applicability and Caveats - [131]
Pearson ER, Del Prato S, Pavo I et al.. “Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.” Diabetes (2025). PMID: 40633089 ↗
L2RCTCited in: Applicability and Caveats - [132]
Mochizuki K, Fuchigami A, Hirose T et al.. “Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study.” Diabetes, obesity & metabolism (2025). PMID: 40563136 ↗
L2RCTCited in: Applicability and Caveats - [133]
Roos PR, van den Burg EL, Schoonakker MP et al.. “Fasting-mimicking diet in type 2 diabetes reduces myocardial triglyceride content: A 12-month randomised controlled trial.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2025). PMID: 39934050 ↗
L1RCTCited in: Applicability and Caveats - [134]
Lu J, Sun S, Shang X et al.. “Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.” International journal of medical sciences (2026). PMID: 42328113 ↗
L2SR_OBSCited in: Applicability and Caveats - [135]
Shabu A, Naqvi SM, Hesari F et al.. “Effect of Oral Hypoglycaemic Agents on Carotid Artery Intima-Media Thickness in Patients With Cardiovascular Disease and/or Diabetes-A Systematic Review.” Endocrinology, diabetes & metabolism (2025). PMID: 41267359 ↗
L1SR_OBSCited in: Applicability and Caveats - [136]
Eleftheriadou A, Riley D, Zhao SS et al.. “Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.” Diabetologia (2024). PMID: 38584180 ↗
L3OTHERCited in: Applicability and Caveats - [137]
Cavalcante PN, Barreto J, Kimura-Medorima ST et al.. “Dapagliflozin reduces the white coat effect on systolic blood pressure of patients with type 2 diabetes: a post-hoc analysis from the ADDENDA-BHS 2 trial.” Current medical research and opinion (2024). PMID: 39706688 ↗
L2RCTCited in: Applicability and Caveats - [138]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: Applicability and Caveats - [139]
Borooghani H, Arabi M, Kazemi Jahromi M. “Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.” Iranian journal of kidney diseases (2025). PMID: 42234904 ↗
L1SR_OBSCited in: Applicability and Caveats - [140]
Mather KJ, Mari A, Heise T et al.. “Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38795393 ↗
L1RCTCited in: On the Horizon - [141]
Pedersen AKN, Gormsen LC, Nielsen S et al.. “Metformin Improves the Prerequisites for FGF21 Signaling in Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37776319 ↗
L1RCTCited in: On the Horizon - [142]
Simonson DC, Testa MA, Ekholm E et al.. “Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38412282 ↗
L2RCTCited in: On the Horizon - [143]
Cordiner RLM, Bedair K, Mari A et al.. “Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38267622 ↗
L2RCTCited in: On the Horizon - [144]
Zeitler P, Galindo RJ, Davies MJ et al.. “Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.” Diabetes care (2024). PMID: 38639997 ↗
L2RCTCited in: On the Horizon - [145]
Latva-Rasku A, Rebelos E, Tuisku J et al.. “SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study.” Diabetes care (2024). PMID: 38941156 ↗
L1RCTCited in: On the Horizon - [146]
Rasouli N, Younes N, Ghosh A et al.. “Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.” Diabetes care (2024). PMID: 38211595 ↗
L1RCTCited in: On the Horizon - [147]
Chen ZZ, Lu C, Dreyfuss JM et al.. “Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes.” Diabetes care (2024). PMID: 38935559 ↗
L2RCTCited in: On the Horizon - [148]
Wang H, Cordiner RLM, Huang Y et al.. “Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.” Diabetes care (2023). PMID: 36944118 ↗
L2RCTCited in: On the Horizon - [149]
Cengiz E, Danne T, Ahmad T et al.. “International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes.” Hormone research in paediatrics (2025). PMID: 39884261 ↗
L1GUIDELINECited in: On the Horizon - [150]
Hansen LS, Gasbjerg LS, Brønden A et al.. “The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.” European journal of endocrinology (2024). PMID: 39049802 ↗
L1RCTCited in: On the Horizon - [151]
Małecki MT, Batterham RL, Sattar N et al.. “Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.” Diabetes care (2023). PMID: 37824793 ↗
L2TRIAL_NONRANDOMCited in: On the Horizon - [152]
Zhang L, Zhang Y, Shen S et al.. “Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.” The lancet. Diabetes & endocrinology (2023). PMID: 37414069 ↗
L1RCTCited in: On the Horizon - [153]
Sandforth A, von Schwartzenberg RJ, Arreola EV et al.. “Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).” The lancet. Diabetes & endocrinology (2023). PMID: 37769677 ↗
L2RCTCited in: On the Horizon - [154]
Feig DS, Sanchez JJ, Murphy KE et al.. “Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.” The lancet. Diabetes & endocrinology (2023). PMID: 36746160 ↗
L1RCTCited in: On the Horizon - [155]
Adler AI, Coleman RL, Leal J et al.. “Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).” Lancet (London, England) (2024). PMID: 38772405 ↗
L1RCTCited in: On the Horizon - [156]
Nadeau KJ, Arslanian SA, Bacha F et al.. “Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial.” Diabetologia (2024). PMID: 39706874 ↗
L2RCTCited in: On the Horizon - [157]
Moens de Hase E, Neyrinck AM, Rodriguez J et al.. “Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention.” Diabetologia (2023). PMID: 37897566 ↗
L2RCTCited in: On the Horizon - [158]
Garrib A, Kivuyo S, Bates K et al.. “Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.” Diabetologia (2023). PMID: 37460828 ↗
L1RCTCited in: On the Horizon - [159]
Xie C, Iroga P, Bound MJ et al.. “Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.” Diabetologia (2024). PMID: 38561463 ↗
L1RCTCited in: On the Horizon - [160]
Davidsen L, Jensen MH, Cook ME et al.. “Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study.” European journal of endocrinology (2024). PMID: 38134412 ↗
L2COHORTCited in: On the Horizon - [161]
Krishnan A, Schneider CV, Hadi Y et al.. “Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.” Diabetologia (2023). PMID: 38117293 ↗
L2COHORTCited in: On the Horizon - [162]
Li Z, Lin C, Cai X et al.. “Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials.” Alzheimer's research & therapy (2024). PMID: 39716328 ↗
L1SR_MA_RCTCited in: On the Horizon - [163]
Hitt TA, Hannon TS, Magge SN. “Approach to the Patient: Youth-Onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37584397 ↗
L5OTHERCited in: On the Horizon - [164]
Chung ST, Davis F, Patel T et al.. “Reevaluating First-line Therapies in Youth-Onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37624230 ↗
L5OTHERCited in: On the Horizon - [165]
Flowers E, Aouizerat BE, Kanaya AM et al.. “MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36477577 ↗
L2OTHERCited in: On the Horizon - [166]
Yu OHY, Suissa S. “Metformin and Cancer: Solutions to a Real-World Evidence Failure.” Diabetes care (2023). PMID: 37185680 ↗
L5REVIEW_NARRATIVECited in: On the Horizon - [167]
Bao Y, Hu Y, Shi M et al.. “SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.” Diabetes, obesity & metabolism (2024). PMID: 39639835 ↗
L1SR_OBSCited in: On the Horizon - [168]
Shabil M, Khatib MN, Ballal S et al.. “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.” BMC endocrine disorders (2024). PMID: 39551761 ↗
L1SR_OBSCited in: On the Horizon - [169]
Gunabalasingam S, Kyrka A, Hopkins L et al.. “Interventions in women with type 2 diabetes mellitus in the pre-pregnancy, pregnancy and postpartum periods to optimise care and health outcomes: A systematic review.” Diabetic medicine : a journal of the British Diabetic Association (2024). PMID: 39527377 ↗
L1SR_OBSCited in: On the Horizon - [170]
Xie Y, Bowe B, Xian H et al.. “Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.” The lancet. Diabetes & endocrinology (2023). PMID: 37499675 ↗
L2OTHERCited in: On the Horizon - [171]
Munshi MN, Venditti EM, Tjaden AH et al.. “Long-term impact of Diabetes Prevention Program interventions on walking endurance.” Frontiers in public health (2024). PMID: 39744353 ↗
L1RCTCited in: On the Horizon - [172]
Takahashi A, Nomoto H, Yokoyama H et al.. “Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).” Diabetes, obesity & metabolism (2024). PMID: 39726204 ↗
L1RCTCited in: On the Horizon - [173]
Rosell-Díaz M, Fernández-Real JM. “Metformin, Cognitive Function, and Changes in the Gut Microbiome.” Endocrine reviews (2024). PMID: 37603460 ↗
L5REVIEW_NARRATIVECited in: On the Horizon